Effects of propofol, dexmedetomidine, and midazolam on postoperative cognitive dysfunction in elderly patients: a randomized controlled preliminary trial

For older adults undergoing surgery, a hidden risk lingers beyond the operating room: postoperative cognitive dysfunction (POCD). This condition—characterized by foggy memory, scattered attention, or slowed decision-making—can derail recovery and lower quality of life. Up to 62% of seniors with hip fractures develop POCD, and anesthesia choices may play a critical role in whether this happens. A 2019 study from Chinese researchers shed light on how three common sedatives—propofol, dexmedetomidine, and midazolam—affect POCD risk in elderly patients getting hip or knee replacements.

Led by Wei-Xia Li, Ru-Yi Luo, and colleagues from China-Japan Friendship Hospital and other top medical centers, the study enrolled 164 patients aged 65 or older scheduled for elective hip or knee arthroplasty. Researchers also recruited 41 non-surgical seniors as a control group to compare cognitive changes over time. All surgical patients received combined spinal-epidural anesthesia (a regional technique that numbs the lower body) with light sedation—targeting a bispectral index (BIS) score of 70–85, which keeps patients calm but responsive. They were randomly assigned to one of three sedatives: propofol, dexmedetomidine, or midazolam.

To measure POCD, the team used five neuropsychological tests before surgery, 7 days later, and 1 year later. The battery included:

Montreal Cognitive Assessment (MoCA): Evaluates overall thinking and memory.
Stroop Color-Word Test: Checks attention, inhibition, and mental speed (e.g., naming the color of a word like “blue” printed in red ink).
Digit Span/ Symbol Tests: Measures working memory and processing speed.
Associative Learning Test: Assesses how well patients link new words or ideas.

POCD was diagnosed using the reliable change index (RCI), a tool that compares a patient’s pre- and post-surgery scores to see if declines are significant (either on two+ tests or across the entire battery).

Key Findings

One week after surgery, 36.6% of patients had POCD—but the sedative choice made a huge difference:

Propofol group: Only 18.2% developed POCD.
Dexmedetomidine group: 40% had POCD.
Midazolam group: 51.9% had POCD.

The propofol advantage was clear: patients in this group scored better on tests of executive function (Stroop test) and associative memory (linking words), suggesting propofol protected skills like focus and new learning. They also had smaller drops in overall MoCA scores compared to midazolam users.

When researchers followed up 1 year later, the gap vanished. Around 10–15% of patients in each group had POCD—no matter which sedative they used.

Why Propofol Shines (and Midazolam Falls Short)

Propofol’s edge likely stems from its neuroprotective properties. As a GABAergic drug, it calms overactive nerve cells and reduces inflammation—two factors tied to POCD. Animal studies show propofol also protects the brain from oxidative stress and cell death.

Midazolam, a benzodiazepine, fared worst. Previous research links benzodiazepines to higher delirium and POCD risk in older adults, and this study confirms that: midazolam users had the highest short-term POCD rates.

Dexmedetomidine, an alpha-2 receptor agonist that mimics natural sleep, had mixed results. While it didn’t lower overall POCD risk at 7 days, it improved some skills (like visuospatial thinking, measured by the MoCA’s clock-drawing test). This suggests dexmedetomidine may help specific cognitive areas but not the broader short-term POCD risk.

What About Confounders?

The study controlled for factors known to affect POCD:

Hypotension: No differences in low blood pressure or vasoactive drug use between groups.
Pain: All patients used patient-controlled epidural analgesia (PCEA) for pain relief, with similar pain scores across groups.

These results suggest the sedative itself—not other surgical factors—drove the short-term POCD differences.

What This Means for Patients and Doctors

For older adults getting hip or knee replacements under spinal anesthesia, propofol is the best choice to minimize short-term POCD risk. While long-term cognitive effects even out, avoiding early POCD can help patients stick to physical therapy, manage medications, and recover more smoothly.

Midazolam, on the other hand, should be used cautiously in seniors—especially since it nearly tripled POCD risk in this study. Dexmedetomidine may still have a role for patients with specific cognitive needs (like visuospatial skills) but isn’t a first-line pick for reducing overall POCD.

Limitations and Next Steps

The study was done at a single hospital with a relatively small group, so results need confirmation in larger, more diverse populations. Additionally, a few patients were lost to follow-up at 1 year, and blood transfusion data was too limited to analyze. Still, as one of the first RCTs to compare these three sedatives in regional anesthesia, it provides valuable guidance for clinicians.

Final Takeaway

POCD is a silent threat to older surgical patients, but anesthesia choices can mitigate risk. This study adds strong evidence that propofol—when used for light sedation—protects short-term cognitive function better than dexmedetomidine or midazolam. For seniors preparing for hip or knee surgery, this could mean a clearer mind in the weeks after procedure—and a faster return to daily life.

The study was led by Wei-Xia Li, Ru-Yi Luo, Chao Chen, Xiang Li, Jing-Sheng Ao, Yue Liu, and Yi-Qing Yin from the Department of Anesthesiology at China-Japan Friendship Hospital, along with colleagues from The Second Xiangya Hospital of Central South University, Shantou Central Hospital, and Fu Xing Hospital of Capital Medical University. It was published in the Chinese Medical Journal in 2019.

doi.org/10.1097/CM9.0000000000000098

Was this helpful?

0 / 0